Hepatic arterial infusion chemotherapy for patients with hepatocellular carcinoma: Applicability in Western countries

IF 4 3区医学 Q1 PHARMACOLOGY & PHARMACY

Current Opinion in Pharmacology Pub Date : 2023-06-01 DOI:10.1016/j.coph.2023.102362

MinKe He , ShuYue Liu , ZhiCheng Lai , ZeFeng Du , QiJiong Li , Li Xu , Anna Kan , JianXian Shen , Ming Shi

引用次数: 0

Abstract

Hepatic arterial infusion chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX-HAIC) has shown a strong anti-tumor effect in hepatocellular carcinoma in China. Different from hepatocellular carcinoma in China, hepatocellular carcinoma in Western countries is caused by hepatitis C and alcoholic liver disease, and is often diagnosed at an early stage, when the tumor is small or the thrombus is not serious. Although there are no reports of FOLFOX-HAIC efficacy for hepatocellular carcinoma in Western countries, FOLFOX-HAIC can be used in patients with large tumors (> 5 cm) (or T3 by TNM stage), and rich blood supply.

查看原文本刊更多论文

肝细胞癌患者肝动脉灌注化疗在西方国家的适用性

奥沙利铂、5-氟尿嘧啶和亚叶酸（FOLFOX-HAIC）肝动脉灌注化疗在中国肝细胞癌中显示出强大的抗肿瘤作用。与我国肝细胞癌不同，西方国家的肝细胞癌是由丙型肝炎和酒精性肝病引起的，通常在肿瘤较小或血栓不严重的早期诊断。尽管在西方国家没有FOLFOX-HAIC治疗肝细胞癌的疗效报告，但FOLFOX-HAIC可用于大肿瘤（>；5cm）（或TNM分期为T3）和丰富血液供应的患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in Pharmacology 医学-药学

CiteScore

8.80

自引率

2.50%

发文量

131

审稿时长

4-8 weeks

期刊介绍： Current Opinion in Pharmacology (COPHAR) publishes authoritative, comprehensive, and systematic reviews. COPHAR helps specialists keep up to date with a clear and readable synthesis on current advances in pharmacology and drug discovery. Expert authors annotate the most interesting papers from the expanding volume of information published today, saving valuable time and giving the reader insight on areas of importance.